Inhaled Δ(9)-tetrahydrocannabinol does not enhance oxycodone-induced respiratory depression: randomised controlled trial in healthy volunteers

Autor: Cornelis Jan van Dam, Rutger van der Schrier, Monique van Velzen, Maarten van Lemmen, Pieter Simons, Kiki W.K. Kuijpers, Simone Jansen, Mikael A. Kowal, Erik Olofsen, Cornelis Kramers, Albert Dahan, Marieke Niesters
Rok vydání: 2023
Předmět:
Zdroj: British Journal of Anaesthesia, 130, 485-493
British Journal of Anaesthesia, 130, 4, pp. 485-493
ISSN: 2021-0000
0007-0912
Popis: Contains fulltext : 291652.pdf (Publisher’s version ) (Open Access) BACKGROUND: In humans, the effect of cannabis on ventilatory control is poorly studied, and consequently, the effect of Δ(9)-tetrahydrocannabinol (THC) remains unknown, particularly when THC is combined with an opioid. We studied the effect of THC on breathing without and with oxycodone pretreatment. We hypothesised that THC causes respiratory depression, which is amplified when THC and oxycodone are combined. METHODS: In this randomised controlled crossover trial, healthy volunteers were administered inhaled Bedrocan® 100 mg (Bedrocan International B.V., Veendam, The Netherlands), a pharmaceutical-grade high-THC cannabis variant (21.8% THC; 0.1% cannabidiol), after placebo or oral oxycodone 20 mg pretreatment; THC was inhaled 1.5 and 4.5 h after placebo or oxycodone intake. The primary endpoint was isohypercapnic ventilation at an end-tidal Pco(2) of 55 mm Hg or 7.3 kPa (V(E)55), measured at 1-h intervals for 7 h after placebo/oxycodone intake. RESULTS: In 18 volunteers (age 22 yr [3]; 9 [50%] female), oxycodone produced a 30% decrease in V(E)55, whereas placebo was without effect on V(E)55. The first cannabis inhalation resulted in V(E)55 changing from 20.3 (3.1) to 23.8 (2.4) L min(-1) (P=0.06) after placebo, and from 11.8 (2.8) to 13.0 (3.9) L min(-1) (P=0.83) after oxycodone. The second cannabis inhalation also had no effect on V(E)55, but slightly increased sedation. CONCLUSIONS: In humans, THC has no effect on ventilatory control after placebo or oxycodone pretreatment. CLINICAL TRIAL REGISTRATION: 2021-000083-29 (EU Clinical Trials Register.). 2A p.
Databáze: OpenAIRE
Externí odkaz: